Combat-related intraocular foreign body types vary, but are often vision-threatening and require an adaptable treatment approach.

The authors noted that this is the first prospective case series to apply a structured, protocol-based approach to ...

LEDGEWOOD, N.J. (PIX11) — A company claiming to be “America’s Largest Ophthalmic Pharmacy” has issued a recall for multiple eye drop products for the presence of glass-like particles, according to the ...

Port fuel injection (PFI) was a major milestone in the early '80s. The integration of PFI rapidly changed the way fuel was delivered by increasing fuel economy and improving engine performance. Even ...

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines. Inflammasome Therapeutics has completed enrollment in a multicenter, dose-ranging phase 2 trial (NCT06164587) for its ...

K8, a dual inflammasome inhibitor, is being tested for geographic atrophy in a phase 2 trial involving 30 patients across 9 US centers. Kamuvudines, derived from anti-HIV drugs, retain ...

NEWTON, Mass.--(BUSINESS WIRE)--#NRTIs--Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ophthalmic and ...

Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy Inflammasome Therapeutics, a ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also ...